Literature DB >> 25188863

Primary cutaneous NK/T-cell lymphoma, nasal type and CD56-positive peripheral T-cell lymphoma: a cellular lineage and clinicopathologic study of 60 patients from Asia.

Katsuyoshi Takata1, Min-Eui Hong, Panitta Sitthinamsuwan, Florence Loong, Soo-Yong Tan, Jau-Yu Liau, Pin-Pen Hsieh, Siok-Bian Ng, Sheau-Fang Yang, Tawatchai Pongpruttipan, Sanya Sukpanichnant, Yok-Lam Kwong, Young Hyeh Ko, Yung-Tsu Cho, Wee Joo Chng, Takashi Matsushita, Tadashi Yoshino, Shih-Sung Chuang.   

Abstract

Primary cutaneous, extranodal natural killer/T-cell lymphoma, nasal type (PC-ENKTL), is a rare Epstein-Barr virus (EBV)-associated neoplasm with poorly defined clinicopathologic features. We performed a multinational retrospective study of PC-ENKTL and CD56-positive EBV-negative peripheral T-cell lymphoma (PC-CD56+PTCL) in Asia in an attempt to elucidate their clinicopathologic features. Using immunohistochemistry for T-cell receptors (TCRs), in situ hybridization for EBV, and TCR gene rearrangement, we classified 60 tumors into 51 with PC-ENKTL (20 of NK-cell, 17 T-cell, and 14 indeterminate lineages) and 9 with PC-CD56+PTCL. Tumors of T-cell origin accounted for 46% of PC-ENKTLs with half of these cases being TCR-silent. As compared with T-lineage tumors, PC-ENKTLs of NK-cell lineage had more frequent involvement of regional lymph nodes and more frequently CD8-negative and CD56-positive. Cases of PC-ENKTL showed more frequent tumor necrosis, younger age, and a higher frequency of CD16 and CD30 expression than cases of PC-CD56+PTCL. CD56-positive T-lineage PC-ENKTL tumors (n=8) had more localized disease in the TNM (tumor-node-metastasis) staging and were more often of γδ T-cell origin compared with cases of PC-CD56+PTCL (n=9). PC-ENKTLs and PC-CD56+PTCLs were equally aggressive, with a 5-year overall survival rate of 25%. Tumor necrosis and CD16 expression may serve as useful surrogates for differentiating PC-ENKTL from PC-CD56+PTCL. A single lesion, an elevated lactate dehydrogenase level, and the presence of B symptoms were independent poor prognostic factors for PC-ENKTL in multivariate analysis. Further studies with more cases are warranted to delineate the clinicopathologic features and significance of EBV in these rare lymphomas.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25188863     DOI: 10.1097/PAS.0000000000000312

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  19 in total

1.  Clinicopathological analysis of the hydroa vacciniforme-like lymphoproliferative disorder with natural killer cell phenotype compared with cutaneous natural killer T-cell lymphoma.

Authors:  Guan-Nan Wang; Yong Cui; Wu-Gan Zhao; Ling Li; Xu-Dong Zhang; Yu Chang; Xian-Zheng Gao; Ye Li; Ming-Zhi Zhang; Wen-Cai Li
Journal:  Exp Ther Med       Date:  2018-09-19       Impact factor: 2.447

2.  [Expression of asparagine synthetase in relapsed or refractory extranodal NK/T cell lymphoma].

Authors:  Shao-Jie Wu; Yu-Fa Li; Yu-Jue Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-04-20

3.  Extranodal NK-T Cell Lymphoma, Nasal Type: Retrospective Analysis of Real-World Data.

Authors:  Sneha J Bothra; Pragya Bhandari; Narendra Agrawal; Narender Tejwani; Rayaz Ahmed; Vishvdeep Khushoo; Sumeet Mirgh; Dinesh Bhurani
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-28       Impact factor: 0.900

4.  Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior.

Authors:  Mineui Hong; Taehee Lee; So Young Kang; Suk-Jin Kim; Wonseog Kim; Young-Hyeh Ko
Journal:  Mod Pathol       Date:  2016-03-25       Impact factor: 7.842

5.  Extranasal extranodal NK/T cell lymphoma: A post-transplantation lymphoproliferative disease.

Authors:  Ayda Acar; Ertan Nurlu; Nur Sokmen; Nazan Ozsan; Eren A Davulcu; Can Ceylan
Journal:  Int Wound J       Date:  2019-04-14       Impact factor: 3.315

6.  Rhino-Orbital-Cerebral Mycosis and Extranodal Natural Killer or/and T-Cell Lymphoma, Nasal Type.

Authors:  Dong Ming Li; Li De Lun
Journal:  Front Med (Lausanne)       Date:  2022-06-17

Review 7.  How we treat NK/T-cell lymphomas.

Authors:  Eric Tse; Wei-Li Zhao; Jie Xiong; Yok-Lam Kwong
Journal:  J Hematol Oncol       Date:  2022-06-03       Impact factor: 23.168

8.  Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma.

Authors:  Bethany L Mundy-Bosse; Christoph Weigel; Yue-Zhong Wu; Salma Abdelbaky; Youssef Youssef; Susana Beceiro Casas; Nicholas Polley; Gabrielle Ernst; Karen A Young; Kathleen K McConnell; Ansel P Nalin; Kevin G Wu; Megan Broughton; Matthew R Lordo; Ekaterina Altynova; Everardo Hegewisch-Solloa; Daniel Y Enriquez-Vera; Daniela Dueñas; Carlos Barrionuevo; Shan-Chi Yu; Atif Saleem; Carlos J Suarez; Edward L Briercheck; Hernan Molina-Kirsch; Thomas P Loughran; Dieter Weichenhan; Christoph Plass; John C Reneau; Emily M Mace; Fabiola Valvert Gamboa; David M Weinstock; Yasodha Natkunam; Michael A Caligiuri; Anjali Mishra; Pierluigi Porcu; Robert A Baiocchi; Jonathan E Brammer; Aharon G Freud; Christopher C Oakes
Journal:  Blood Cancer Discov       Date:  2022-03-01

Review 9.  Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas.

Authors:  Jason Yongsheng Chan; Soon Thye Lim
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

10.  Pyoderma gangrenosum preceding the onset of extranodal natural killer/T-cell lymphoma: A case report.

Authors:  Ting-Hua Yang; Chung-Hong Hu; Hsiou-Hsin Tsai
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.